Management Team

Core Group

craig-rosenfeld

CRAIG ROSENFELD, MD, CHIEF EXECUTIVE OFFICER

  • During 20 years practice as a board-certified hematologist and oncologist, devised, conducted and led numerous clinical research protocols from preclinical research to FDA approval, resulting in close to 100 publications in peer reviewed journals and book publications
  • Chief Scientific Officer and Senior Vice President of SuperGen, Inc. (2002-2004), responsible for directing the pivotal clinical trials leading to FDA approval of Dacogen
  • Director of Bone Marrow Transplant programs at the Western Pennsylvania Cancer Institute (1990-1994) and Medical City Dallas Hospital (1994-2001)
kay-noel

KAY NOEL, PHD, CHIEF OPERATING OFFICER

  • Over 30 years experience in pharmaceutical development, with 10 NDA approvals; extensive experience in portfolio development, in-licensing, and out-licensing
  • Co-founder and Chief Operating Officer of Oncoethix SA (sold to Merck)
  • Co-founder and Vice President, Business Development of Oncology Therapeutics Network (sold to Bristol-Myers Squibb)
  • Former Director, Healthcare Business, Cetus Corporation and Director, Biologics R&D, Abbott Laboratories
jim-bobcock

JIM BABCOCK, CHAIRMAN

  • Founder, Cthulhu Ventures LLC, CMD’s founding investor.  As part of his role at Cthulhu Ventures, Jim serves on the boards of a number of companies in which Cthulhu Ventures has invested, including, inter alia, CMD, the Warner Babcock Institute for Green Chemistry LLC, and Collaborative Aggregates LLC
  • Previously, Co-founder, Chief Executive Officer, and ultimately, Chairman of Babcock & Brown, a global investment banking/funds management firm that was listed on the Australian Stock Exchange (ASX)
  • Graduated magna cum laude from Harvard College and Harvard Law School (where he was a member and officer of the Harvard Law Review) and served for a year as a law clerk to Judge James R. Browning of the Ninth Circuit Court of Appeals
ashley-bush

ASHLEY BUSH, MD, PHD, CHIEF SCIENTIFIC OFFICER

  • Professor of Pathology; Director, Oxidation Biology Unit; and NHMRC Australia Fellow at the Florey Institute of Neuroscience and Mental Health (Melbourne, Australia)
  • Research focused on looking at how key proteins interact inappropriately with metals in the brain to cause oxidative stress in diseases including Alzheimer’s and Parkinson’s.  Actively working to develop disease modifying drugs for Alzheimer’s and Parkinson’s disease as well as blood tests for these disorders
  • Authored over 310 publications, with over 22,000 citations, 24 patents and founded 4 biotechnology companies
  • Listed in the Thompson ISI list of The World’s Most Influential Scientific Minds in 2014 & 2015
chris-hill

CHRIS HILL, CHIEF FINANCIAL OFFICER

  • Chris Hill is Chief Financial Officer for Cthulhu Ventures LLC and for a number of the companies in which Cthulhu Ventures, CMD’s founding investor, has invested, including, inter alia, the Warner Babcock Institute for Green Chemistry.
  • Over 20 years experience in finance and information systems management
  • Formerly Chief Financial Officer for Above Board Technologies; President & CEO of Modulus Guitars; and VP Finance for ViTel International, Inc.
ken-goldman

KEN GOLDMAN, IP COUNSEL

  • Intellectual Property Counsel for Cthulhu Ventures LLC and for a for a number of companies in which Cthulhu Ventures, CMD’s founding investor, has invested including CMD and, inter alia, the Warner Babcock Institute for Green Chemistry
  • Over 20 years experience managing IP issues for biotechnology and diagnostics companies
  • Former IP Director at Novartis, Dynavax, Cell Genesys, and Chiron Corporation
james-mccall

JAMES MCCALL BABCOCK, INVESTOR RELATIONS AND BUSINESS DEVELOPMENT

  • James Babcock has been involved with Cthulhu Ventures since its founding, focused primarily on investment analysis and business development, as well as ongoing investment oversight and client/portfolio company relationships
  • CEO of Collaborate Aggregates LLC, one of Cthulhu Ventures’ recent start-ups.
john-warner

JOHN WARNER, PHD, MOLECULAR INVENTIONS AND DEVELOPMENT

  • Founder, President and Chief Technology Officer of the Warner Babcock Institute for Green Chemistry LLC, a portfolio company of Cthulhu Ventures that is applying green chemistry technologies in fields such as biodegradable plastics, personal care products, and solar energy.
  • ŸOne of the two founders of the field of green chemistry, co-authoring the defining text “Green Chemistry: Theory and Practice” with Paul Anastas.
  • Previously, Professor of Chemistry and Plastics Engineering at UMASS Boston and Lowell and senior research scientist at Polaroid Corporation.
  • Among his many awards, in 2011 he was elected a Fellow of the American Chemical Society and named by ICIS as one of the most influential people impacting the global chemical industries and in 2014 he was the recipient of American Society of Chemical Industry’s Perkin Award. He has published over 200 patents, papers and books.
joe-pont

JOE PONT, PHD, DISCOVERY CHEMISTRY

  • Chief Executive Officer of the Warner Babcock Institute for Green Chemistry LLC, a portfolio company of Cthulhu Ventures that is applying green chemistry technologies in the fields such as biodegradable plastics, personal care products, and solar energy.
  • Previously, served in senior R&D and commercial roles in the chemical and pharmaceutical industries in the US and Europe.  Prior to joining WBI, he worked 10 years at Lonza, most recently as Head of R&D and then Vice President of Marketing & Key Account Management.

Outside Scientific Advisors

JOHN PROUDFOOT, PhD

  • Advisor on medicinal chemistry and lead generation and optimization
  • Providing independent consulting services to drug discovery start-ups through Discoverybytes
  • Previously 30 years of experience in the pharmaceutical industry with leadership roles in medicinal chemistry, lead identification, and new concept development
peter-crouch

PETER CROUCH, PHD

  • Advisor on biology of neurodegerative diseases with a focus on ALS/MND
  • Research Fellow, Department of Pathology, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne (Melbourne, Australia)
joe-beckman

JOE BECKMAN, PHD

  • Advisor on biology of neurodegerative diseases with a focus on ALS/MND
  • Principal Investigator and Burgess and Elizabeth Jamieson Chair in Healthspan Research, Linus Pauling Institute; Distinguished Professor, Department of Biochemistry and Biophysics; and Director, Environmental Health Sciences Center, Oregon State University (Corvallis, Oregon, USA)
kevin-barnham

KEVIN BARNHAM, PHD

  • Advisor on neurodegerative diseases with a focus on Parkinson’s Disease
  • Associate Professor, Department of Pharmacology, The University of Melbourne and NHMRC Senior Principal Research Fellow, Florey Institute for Neuroscience and Mental Health (Melbourne, Australia)